Andrew Pearson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6577132/publications.pdf

Version: 2024-02-01

1040018 1474186 9 231 9 9 citations h-index g-index papers 9 9 9 305 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	2.8	24
2	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. European Journal of Cancer, 2022, 166, 145-164.	2.8	28
3	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. European Journal of Cancer, 2022, 173, 71-90.	2.8	9
4	Bromodomain and extra-terminalÂinhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	2.8	10
5	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. Journal of Clinical Oncology, 2021, 39, 2552-2563.	1.6	42
6	Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. European Journal of Cancer, 2021, 153, 142-152.	2.8	12
7	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	2.8	34
8	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. European Journal of Cancer, 2020, 139, 135-148.	2.8	20
9	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	2.8	52